Brägelmann et al. [38] also reported the activation of viral mimicry in the case of BRAF mutant melanoma and MAPK inhibitors (BRAFi + MEKi) further supporting the E2F2-DNMT1 axis as a mechanism of action. Here, E2F2 is linked to melanoma.